Abstract：
CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.
摘要：
CANDOR比较了卡非佐米联合地塞米松和达拉图单抗（KdD）与卡非佐米联合地塞米松（Kd）在成人复发/难治性多发性骨髓瘤（RRMM）中的安全性/有效性。该CANDOR亚组分析基于细胞遗传学风险评估结果。总体反应率（KdDvs.Kd）在高风险组中分别为81%和56%，在标准风险组中分别为87%和79%。无进展生存期中位数为11.2个月，高危人群为7.4个月(风险比，0.56[95%CI，0.34，0.93]），而标准风险组未达到16.6个月（0.56[95%CI，0.39，0.80]）。这些数据支持KdD在RRMM治疗中的疗效，包括高危细胞遗传学患者。
